HIRA says it can't yet predict an outcome. Hanmi is readying its homegrown obesity drug, and some expect a full price fight in Korea.
Recap by typeshit. Full story at Chosunbiz.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Facing Lilly's competition, Novo's chief is pitching muscle preservation and broader health gains as the measure that matters in obesity treatment.
Earlier results had 27.1% on the combo reaching full skin clearance and 10% weight loss at 36 weeks, versus 5.8% on Taltz alone, Lilly said.
Loading…